Explore New Advances in Antibody Discovery
Antibodies play a central role in modern medicine, serving as both therapeutics and as essential tools in diagnostics. While antibody generation against soluble proteins is well established, discovering binders to complex, multipass membrane proteins such as G-protein–coupled receptors (GPCRs) remains one of the greatest technical challenges in the field.
Tuesday
8:00 AM PST/11:00 PM EST
4:00 PM GMT/5:00 PM CET
Webinar:
Advancements in Antibody Discovery
Against Challenging Membrane Targets
Recent innovations are helping scientists overcome these obstacles. Advances in screening methodologies, display technologies, and target-presentation systems are providing effective ways to tackle these difficult targets. One powerful approach combines phage display, a proven and versatile antibody-discovery method, with innovative membrane-protein stabilization platforms, which preserve native protein conformation within a lipid-nanoparticle environment.
In this webinar, Dr. Jens Frauenfeld (Salipro Biotech) will introduce an efficient process to stabilize membrane proteins in their native forms, and Dr. Paul Royle (Bio-Rad) will share insights into phage display and strategies for panning directly against stabilized GPCRs, including methods to preserve key extracellular epitopes and reduce off-target binding.
Join to learn:
- Why GPCRs are vital drug targets and why they’re so challenging
- How membrane-platform technology stabilizes GPCRs for better research results
- How next-generation tools are advancing GPCR-targeting antibody development
- How combining membrane technology with phage display yields high-affinity antibodies for hard-to-hit targets
Speakers
Paul Royle, Custom Antibody
and Biopharma Sales Manager,
Bio-Rad Laboratories
Paul Royle is the EMEA Custom Antibody and Northern Europe Biopharma Sales Manager and has been with Bio-Rad’s Antibody Division for 12 years. Prior to this, he worked in an immunology diagnostics company for almost 7 years. Paul holds a degree and PhD from the University of Nottingham, UK, and has post-doctoral research experience from the University of Warwick, UK.
Jens Frauenfeld, CEO,
Salipro Biotech
Jens Frauenfeld, CEO and Founder of Salipro Biotech AB, developed the Salipro technology for stabilizing membrane proteins at Karolinska Institutet, leading to the start of Salipro Biotech in 2016. Jens holds a PhD from Ludwig Maximilian University of Munich and studied biochemistry in Germany and France with fellowships from Roche and Boehringer Ingelheim Fonds. He is a member of the Prins Daniel Fellowship programme from the Royal Swedish Academy of Engineering Sciences.
Register now!
Can't attend the live webinar? Sign up now and we'll give you access to the recorded webinar.
Required fields